Related Experiment Video
Updated: Jun 24, 2026
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in
Jin-Rong Xia1, Nai-Feng Liu1, Nai-Xun Zhu1
1Department of Gastroenterology, Zhong Da Hospital, Southeast University, Nanjing 210009, China.
Abstract:
Receptor for advanced glycation end products (RAGE) was studied in different stages of carbon tetrachloride induced hepatic fibrosis (HF), and effect of its gene silencing in the HF development was evaluated in rats. Silencing RAGE expression by specific siRNA effectively suppressed NF-kappaB activity, hepatic stellate cell activation, and accumulation of extracellular matrix proteins in the fibrotic liver, and also greatly improved the histopathology and the ultrastructure of liver cells. These effects may be partially mediated by the inhibition on IkappaBalpha degradation. RAGE gene silencing effectively prevented liver from fibrosis, therefore it offers a potential pharmacological tool for anti-HF gene therapy.
Insights
Silencing the Receptor for Advanced Glycation End Products (RAGE) gene effectively prevented liver fibrosis in rats. This approach suppressed key fibrotic markers and improved liver health, offering a potential gene therapy for liver fibrosis.
Area of Science:
- Biomedical research
- Molecular biology
- Hepatology
Background:
- Hepatic fibrosis (HF) is a significant health concern.
- The Receptor for Advanced Glycation End Products (RAGE) role in HF is not fully understood.
Purpose of the Study:
- To investigate RAGE's role in carbon tetrachloride-induced hepatic fibrosis in rats.
- To evaluate the therapeutic potential of RAGE gene silencing in preventing HF.
Main Methods:
- Carbon tetrachloride was used to induce hepatic fibrosis in rats.
- RAGE expression was silenced using specific small interfering RNA (siRNA).
- Key molecular markers, including NF-kappaB activity, stellate cell activation, and extracellular matrix accumulation, were assessed.
Main Results:
- RAGE gene silencing significantly suppressed NF-kappaB activity and hepatic stellate cell activation.
- Silencing RAGE reduced extracellular matrix protein accumulation in the fibrotic liver.
- Histopathology and liver cell ultrastructure were markedly improved following RAGE gene silencing.
Conclusions:
- RAGE plays a crucial role in the development of hepatic fibrosis.
- RAGE gene silencing, potentially via inhibition of IkappaBalpha degradation, is a promising therapeutic strategy for anti-fibrosis gene therapy.
- Targeting RAGE offers a potential new avenue for treating liver fibrosis.
